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Background: Extracellular matrix (ECM) is known to maintain epithelial integrity. In carcinogenesis ECM degradation
triggers metastasis by controlling migration and differentiation including cancer stem cell (CSC) characteristics.
The ECM-modulator inter- α-trypsin inhibitor heavy chain family member five (ITIH5) was recently identified as
tumor suppressor potentially involved in impairing breast cancer progression but molecular mechanisms underlying
its function are still elusive.
Methods: ITIH5 expression was analyzed using the public TCGA portal. ITIH5-overexpressing single-cell clones
were established based on T47D and MDA-MB-231 cell lines. Colony formation, growth, apoptosis, migration,
matrix adhesion, traction force analyses and polarization of tumor cells were studied in vitro. Tumor-initiating
characteristics were analyzed by generating a metastasis mouse model. To identify ITIH5-affected pathways
we utilized genome wide gene expression and DNA methylation profiles. RNA-interference targeting the ITIH5-
downstream regulated gene DAPK1 was used to confirm functional involvement.
Results: ITIH5 loss was pronounced in breast cancer subtypes with unfavorable prognosis like basal-type tumors.
Functionally, cell and colony formation was impaired after ITIH5 re-expression in both cell lines. In a metastasis
mouse model, ITIH5 expressing MDA-MB-231 cells almost completely failed to initiate lung metastases. In these
metastatic cells ITIH5 modulated cell-matrix adhesion dynamics and altered biomechanical cues. The profile of
integrin receptors was shifted towards β1-integrin accompanied by decreased Rac1 and increased RhoA activity
in ITIH5-expressing clones while cell polarization and single-cell migration was impaired. Instead ITIH5 expression
triggered the formation of epithelial-like cell clusters that underwent an epigenetic reprogramming. 214 promoter
regions potentially marked with either H3K4 and /or H3K27 methylation showed a hyper- or hypomethylated
DNA configuration due to ITIH5 expression finally leading to re-expression of the tumor suppressor DAPK1.
In turn, RNAi-mediated knockdown of DAPK1 in ITIH5-expressing MDA-MB-231 single-cell clones clearly restored
cell motility.
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Conclusions: Our results provide evidence that ITIH5 triggers a reprogramming of breast cancer cells with known
stem CSC properties towards an epithelial-like phenotype through global epigenetic changes effecting known
tumor suppressor genes like DAPK1. Therewith, ITIH5 may represent an ECM modulator in epithelial breast tissue
mediating suppression of tumor initiating cancer cell characteristics which are thought being responsible for the
metastasis of breast cancer.
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Turnover of the extracellular matrix (ECM) is a critical
step in various aspects of tumor cell biology, e.g. in
orchestrating breast cancer cell differentiation driving
malignancy and metastasis [1, 2]. Inter-α-trypsin inhibi-
tory (ITI) proteins comprise a family of secreted serine
protease inhibitors found in both the ECM and in the
blood circulation [3]. ITIs are composed of a light chain,
also called Bikunin, and different homologous heavy
chains (i.e. ITIHs). ITIHs are covalently linked to
Bikunin and thereby form a structural and functionally
unique protein with a plasma protease inhibitory activity
[4]. Beyond this the biological function of ITI heavy
chains remains largely unknown. Trimming of precursor
ITIH proteins at a conserved cleavage site unmasks a C-
terminal amino acid [4], which is involved in hyaluronic
acid (HA) binding [5]. Owing to that ITI heavy chains
were originally referred to as serum-derived HA associ-
ated proteins (SHAPs) [6], implicating a wide spectrum
of biological activities. HA that is the major proteogly-
can of the ECM interacts with a large number of HA-
binding proteins (HABPs) [4] like HA-receptors CD44
and RHAMM [7, 8]. Unlike all other described HABPs,
ITI heavy chains are covalently linked with HA [3],
whose complexation generate stable “cable-like struc-
tures” supporting ECM integrity. In 1994 Chen and
colleagues showed that ITI heavy chains are involved in
organizing and controlling of the cumulus-oocyte expan-
sion [9]. In carcinogenesis of various tumor entities,
accumulating studies propose a tumor suppressive role
of ITI heavy chains mediated by their ECM-stabilizing
activity [10–12]. ITIH1 and ITIH3, for instance, have
been demonstrated to cause clear retardation of lung
metastasis in vivo [12] thereby suggesting an important
role of ITI heavy chains in repressing malignant diseases
independently of Bikunin.
In 2004 we identified ITIH5 as the fifth heavy chain
member of the ITI family [13]. ITIH5 contains all struc-
tural features found in ITIH1-3, including distinct func-
tional domains (VIT and vWA) and the conserved
cleavage site. Nevertheless, its expression pattern differs
from that of other heavy chains, i.e. ITIH5 is abundantly
expressed in the placenta and moderately expressed in
various organs such as the mammary gland [13]indicating a local, tissue-specific function. ITIH5 dys-
function has been shown to contribute to inflammatory
skin diseases [14] and obesity, thus potentially acting as
regulator of human metabolism [15]. In tumor develop-
ment, downregulation of ITIH5 caused by aberrant
DNA hypermethylation has been reported in breast
cancer [16, 17], bladder cancer [18], colon cancer [19],
gastric cancer [20] and lung cancer [21]. Based on an
integrated genomic and transcriptomic approach Wu
and colleagues recently demonstrated rare somatic
ITIH5 gene mutations in lung cancer whose frequency
increased up to 6% in corresponding metastases [22].
Loss of ITIH5 expression in breast and bladder cancer
has been associated with clinical parameters of malig-
nant progression and metastasis [16, 18, 23] predicting
poor prognosis in both entities. These findings
strengthen a putative role of ITIH5 as a tumor suppres-
sor in various tumor types, but mechanisms of its func-
tion have not been described so far.
In the present study we give clear evidence that the
ECM modulator ITIH5 is involved in controlling breast
cancer cell migration and colonization in vitro and
in vivo. Moreover, ITIH5 drives an epigenetic repro-
gramming that reverses the aggressive phenotype of
basal-like MDA-MB-231 cancer cells to an epithelial-like
phenotype involving re-expression of the well-known
tumor suppressor gene DAPK1.
Results
Loss of ITIH5 mRNA expression is predominant in breast
tumors of the luminal B, HER2-enriched and basal-type
subtype
Previously, we identified aberrant ITIH5 promoter hyperme-
thylation as the molecular cause for its gene inactivation in
breast cancer, which was associated with unfavorable prog-
nosis [16]. Therefore, we initially aimed to decipher ITIH5
hypermethylation and its subtype specific expression in a
large dataset of The Cancer Genome Atlas (TCGA) [24, 25],
in total comprising 1095 different breast cancer samples,
113 normal breast tissues and 7 distant metastases derived
from primary breast tumors.
By comparison of breast cancer with healthy control
samples, a prevalent loss of ITIH5 expression was found
in primary breast tumors (median fold-change (FC): 18-
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(n = 7) we still observed a clear absence of ITIH5 mRNA
expression (median FC: 23.5-fold downregulation). Clas-
sifying this data set by intrinsic breast cancer subtypes
based on Hu et al. [26] we furthermore revealed a pro-
nounced downregulation of ITIH5 mRNA in luminal B
(median FC: 31.4-fold downregulation), HER2-enriched
(median FC: 22.1-fold downregulation) and basal-like
breast cancer (median FC: 25.7-fold downregulation)
(Fig. 1b), i.e. breast cancer subtypes known to be associ-
ated with high risk for metastasis. In this data set, uni-
variate Kaplan-Meier analyses showed that nodal-
negative patients with high ITIH5 expression tend
(p = 0.057) to have longer overall survival when com-
pared with low ITIH5 expression (Fig. 1c). In patients
lacking distant metastases at initial diagnosis high ITIH5
expression is significantly (p < 0.05) associated with a
longer overall survival when compared with tumors
showing low ITIH5 expression (Fig. 1d).
ITIH5 promotes apoptosis while suppressing colony
growth of breast cancer cells and mediates a
morphological shift of metastatic cells in vitro
Addressing the role of ITIH5 in breast cancer, two dif-
ferent in vitro tumor models were generated reflectingFig. 1 ITIH5 expression loss in breast cancer subtypes and distant metastas
data portal. a Box plot demonstrating a significant loss of ITIH5 mRNA expre
from primary breast tumors, ns: not significant, ***p < 0.001. b Breast tumor
***p < 0.001. c-d Kaplan-Meier analyses display OS of nodal-negative (pN0,
high ITIH5 (green curve) and low/intermediate ITIH5 mRNA expression (blueboth the luminal and basal subtype. Upon stable trans-
fection using a full-length ITIH5 cDNA pBK-CMV ex-
pression vector (ΔpBK-ITIH5 clones, also referred to as
ITIH5) or the empty vector alone (ΔpBK-mock clones,
also referred to as mock), single-cell clones were gener-
ated based on well-differentiated, luminal T47D tumor
cells (Fig. 2a) and on the metastatic, basal-type MDA-
MB-231 breast cancer cell line (Fig. 2b).
At first, the functional impact of forced overexpression of
ITIH5 on tumor colony growth was studied using 2D col-
ony formation assays in vitro. Macroscopic analysis of grown
colonies clearly visualized reduction in colony size in de-
pendency of ITIH5 overexpression in both (T47D and
MDA-MB-231) in vitro models (Fig. 2c and d). Densitomet-
ric evaluation of grown colonies significantly confirmed re-
duced colony growth mediated by ITIH5 expression.
Colony formation was suppressed in ITIH5-expressing
T47D single cell clones (n = 3) by 47.8% (Fig. 2c) and in
MDA-MB-231 (n = 4) by 49.0% (Fig. 2d) compared to inde-
pendent mock control clones, respectively. In line XTT pro-
liferation analyses significantly demonstrated reduced cell
growth in both cell lines in dependence of ITIH5 overex-
pression (Fig. 2e and f). Using a caspase-3/7 apoptosis assay,
we further showed increased by 92.6% (p < 0.01) pro-
grammed cell-death in ITIH5-expressing T47D cloneses. a-b Illustration of ITIH5 mRNA expression based on the TCGA
ssion in primary breast tumors and distant metastases derived
samples stratified by subtypes [28], ns: not significant, **p < 0.01;
c) and non-metastatic (pM0, d) breast cancer patients stratified by
curve)
Fig. 2 ITIH5 impairs cell growth and colonization of breast cancer cells and induce a phenotype shift in vitro. a ITIH5 gain-of-function model of
luminal breast cancer cells: Ectopic ITIH5 expression in transfected T47D ΔpBK-ITIH5 clones was confirmed by Western blotting. A specific signal
of the ectopic ITIH5 protein is detectable only in T47D ITIH5 clones. β-actin served as loading control. b ITIH5 gain-of-function model of basal-
type breast cancer cells: Ectopic ITIH5 expression in transfected MDA-MD-231 ΔpBK-ITIH5 single-cell clones was confirmed by Western blotting.
A specific signal of the ectopic ITIH5 protein is detectable in MDA-MB-231 ITIH5 clones. β-actin served as loading control. c Colony growth of
luminal T47D breast cancer cells in dependency of ITIH5 re-expression. Box plot presents averages of triplicate experiments based on three
independent T47D ITIH5 and three T47D mock clones. Left: Representative wells with grown ITIH5 as well as mock colonies are shown. Right:
Densitometrical evaluation of colony growth after 14 days. d Colony growth of basal-type MDA-MB-231 breast cancer cells due to stable ITIH5
re-expression. Box plot presents averages of triplicate experiments based on four independent MDA-MB-231 ITIH5 and two MDA-MB-231 mock
clones. Left: Representative wells with grown ΔpBK-ITIH5 as well as mock colonies are shown. Right: Densitometrical evaluation of colony growth
after 14 days. e-f XTT proliferation assay was performed. T47D e and MDA-MB-231 f ITIH5 single-cell clones showed reduced cell growth compared
with ΔpBK-mock controls. The baseline level at 24 h was set to 1. g-h Caspase 3/7 activity as indicator of apoptosis in independent T47D g and MDA-
MB-231 h mock and ITIH5 single-cell clones (n = 3, respectively). Box plot demonstrates relative apoptosis rate. Horizontal lines: grouped medians. Boxes:
25–75% quartiles. Vertical lines: range, minimum and maximum, **p < 0.01. i Comparison of morphological MDA-MB-231 colony growth patterns of
ITIH5 and mock clones. Right images: colony edges. Representative light-micrographs are shown. j Comparison of single-cell plasticity showing different
confluence of both MDA-MB-231 ITIH5 and mock clones. Representative SEM-micrographs are shown. Scale bar = 20 μm
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(n= 3 independent clones) (Fig. 2g). ITIH5 expression had
no sustained effect on apoptosis in MDA-MB-231 cells
(Fig. 2h). In turn, microscopic analyses revealed fundamental
changes in growth patterns of MDA-MB-231 ΔpBK-ITIH5
cancer cells (Fig. 2i and j) but not in T47D transfected cells
(data not shown). While mock-transfected MDA-MB-231
cells retained a scattered colony growth, ITIH5-expressing
MDA-MB-231 cells formed independently of the amount of
forced ITIH5 expression of tested clones (n= 6; Additional
file 1) tightly packed colony structures lacking cell spreading
at the colony periphery (Fig. 2i). Scanning electron mi-
croscopy analyses (Fig. 2j) finally confirmed pro-
nounced morphological changes of independent MDA-
MB-231 ITIH5 cell clones at high and low density.
ΔpBK-mock cells showed a mesenchymal-like morph-
ology characterized by an elongated cell shape. In con-
trast, ITIH5-expressing MDA-MB-231 cells grew in a
monolayer with a cuboidal single-cell shape indicating
a profound impact of ITIH5 action in this metastatic
breast cancer cell line.ITIH5 suppresses lung colonization by metastatic
MDA-MB-231 breast cancer cells in mice
To study the putative tumor suppressive function of
ITIH5 under physiological conditions, an experimental
in vivo metastasis assay was performed using single-cell
clones of the highly metastatic MDA-MB-231 cell line.
By day 50 after tumor cell injection (i.v.) mice were
three-dimensionally (3D) screened using whole-body
non-invasive μCT scans to evaluate major organs of
metastatic tumor growth (Fig. 3a). No metastases were
found in brain or liver, whereas lungs of control mice
(injected with MDA-MB-231 ΔpBK-mock single-cell
clones) presented high numbers of macro-metastases,
i.e. up to 9 metastases/mouse (Fig. 3b and c). Overall 6
out of 7 (85%) mice treated with MDA-MB-231 mock
cells showed lung metastases. In comparison to that, the
number of macro-nodules in the lung was clearly
decreased when mice received MDA-MB-231 tumor
cells expressing ITIH5 as confirmed by RT-PCR (Fig. 3d).
Only in 3 out of 7 (43%) mice macro-metastases were
detected. The highest number of metastases was 2
nodules per mouse (Fig. 3b). Based on histo-
pathological assessment of lung sections, we con-
firmed a clear reduction of macro-metastases by
ITIH5 (p < 0.05) (Fig. 3e and f ). More interestingly,
remarkable differences in the number of micro-
metastases (<0.1 cm) were found between the ITIH5-
group and control mice (Fig. 3f ). While control mice
exhibited high numbers of micro-metastases (median
number: 33.25) that spread over the whole lung tis-
sue, experimental mice receiving ITIH5-expressingtumor cells only presented very low numbers (median
number: 0.5) of small tumor nodules.
ITIH5 remodels ECM composition, enhances cell-matrix
adhesion and contractile cell force generation
So far, data on biological processes and pathways
affected by ITI heavy chains besides HA-stabilization are
still lacking. Therefore, a transcriptomic micro-array
profiling approach was performed followed by gene
ontology (GO) annotations using a gene set comparison
analysis. Interestingly, over-represented gene annotations
confirmed an impact of ITIH5 expression on biological
processes (BP) such as “lipid catabolic process” in this
metastatic MDA-MB-231 cancer cell line (Table 1) that
is in line with recently published data [15]. In addition
to those annotations, we further revealed an association
of ITIH5 expression with categories like “cell adhesion”
or “epithelial cell differentiation”. Interestingly, enrich-
ment of collagens was also shown including upregulation
of both transcripts (COL4A1, FC: 1.73 and COL4A2, FC:
1.53) of the basement membrane (BM) constituent colla-
gen type IV (Table 1). We confirmed increased expres-
sion of collagen type IV on mRNA and on protein level
in MDA-MB-231 ΔpBK-ITIH5 cells (Fig. 4a and b).
Experimentally, MDA-MB-231 ΔpBK-ITIH5 clones
showed altered cell-matrix adhesion dynamics in vitro. On
both substrates, i.e. on Matrigel™ that imitates the BM and
on HA, ITIH5 expression led to an increased cell-matrix
adhesion (Matrigel™: +52.6%, p < 0.001; HA: +37.4%;
p < 0.001) compared to mock control clones (Fig. 4c).
Based on this result, cellular traction forces was investi-
gated as potential trigger that could contribute to the
modulation of cell behavior, such as enhanced matrix ad-
hesion [27, 28]. For this purpose traction force microscopy
(TFM) was used as standard method to quantify contractile
forces that cells exert on their surrounding ECM [29, 30].
In order to recapitulate a tumor relevant microenviron-
ment, substrates of 15 kPa stiffness were used for cell adhe-
sion. Such ECM compliance lies in the range of activated
breast tumor stroma [31], which results from continuous
ECM-stiffening during cancer progression driving invasion
and tissue tropism of metastatic tumor cells [32]. In vitro
traction force analyses revealed strengthened contractile
cell force generation during cell-matrix adhesion of
ITIH5 expressing cells (Fig. 4d). The direct compari-
son with corresponding mock control clones showed
a median increase in cell force of 43.9% in MDA-
MB-231 ITIH5 clones (ΔpBK-mock: 107.5 nN, ΔpBK-
ITIH5: 162.6 nN; p < 0.0001) (Fig. 4e).
ITIH5 modulates integrin signaling that is associated with
inhibition of mesenchymal single-cell migration in vitro
Next, we aimed to decipher the dynamics of the ob-
served mechanical alterations in ECM-cell interactions
Fig. 3 ITIH5 suppresses lung colonization of basal-type breast cancer cells in vivo. a In vivo μCT screening highlighted metastatic growth in
mouse lungs. Representative 2D (a–d) and 3D (e + f) images of the lung after contrast-agent application and 3D volume rendering are shown.
Macro-metastases foci (white circles; green-colored after segmentation) in mice intravenously injected with MDA-MB-231 mock cells (control set) in
the pleural space. Red: vascular structures. Blue: tracheobronchial system. b Quantification of metastases by in vivo μCT analyses: Number and
nodules size of lung metastases for each mice (n = 7) of the ITIH5 set (ITIH5 clones) compared with the control set (n = 7) is illustrated. c Box plot
illustrating reduced numbers of grown metastases in mice injected with MDA-MB-231 ITIH5 cells. d Human ITIH5 mRNA in ITIH5-induced lung
tumors compared with ΔpBK-mock-induced tumors. Columns: Mean of triplicate determinations. Error bars, + standard error of margin (s.e.m.).
e Representative H&E stained metastases of each size category of mock-treated animals. Black arrows: tumor nodules. Framed rectangle regions
are separately enlarged. Scale bar: 100 μm. f Box plot grouped by three metastases size categories verified a decrease of metastasis growth in mice
injected with MDA-MB-231-ITIH5 cells (n = 7) compared with mice of the control set (n = 7), p < 0.05, **p < 0.01
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Table 1 GO annotated biological processes and cellular components
GO category GO ontology GO term Number of genes LS permutation p-value KS permutation p-value
GO:0016337 BP cell-cell adhesion 95 0.00008 0.00001
GO:0016042 BP lipid catabolic process 56 0.00022 0.00231
GO:0016339 BP calcium-dependent cell-cell adhesion 9 0.00221 0.0002
GO:0030855 BP epithelial cell differentiation 72 0.00561 0.00337
GO:0030426 CC growth cone 23 0.00037 0.00219
GO:0030427 CC site of polarized growth 24 0.00053 0.0032
GO:0005578 CC proteinaceous extracellular matrix 86 0.00266 0.00134
GO:0005581 CC collagen 13 0.01644 0.00332
Bold p-values: significant (p ≤ 0.05)
Fig. 4 ITIH5 alters ECM-cell interactions and enhances cell-matrix adhesion and contractile cell force generation. a-b Collagen type IV mRNA and
protein (western blot) expression in ITIH5 and mock clones. β-actin served as loading control. *p < 0.05. c Cell-to-matrix adhesion of ITIH5 and
mock clones MDA-MB-231 clones on MatrigelTM and HA-substrate. ***p < 0.001. d Cell traction force microscopy assay was used to measure
contractile forces that cells exert on elastomeric substrate during cell-matrix adhesion. Representative phase contrast images (PH, upper row) of a
mock clone and an ITIH5 clone adhered onto elastomeric substrates (15 kPa stiffness) are shown. Vector deformation field images (VDF, middle
row) were retrieved from fluorescent nanobead displacement tracking Scale bar: 20 μm. Corresponding area force fields (AFF: lower row) represent
the actual contractile cell force distribution per surface unit (nN/μm2). Red ROIs: Cell outlines were defined to summarize and compare the whole
contractile force exerted by one single cell [nN], *: cell forces of illustrated cells. e Box plots analysis illustrate the overall comparison of contractile
cell force generation of all measured mock clones (1, 2B and #3), and ITIH5-clones (4, 7 and #12). Box plots: Horizontal lines: grouped medians.
Boxes: 25–75% quartiles. Vertical lines: range, peak and minimum; ***p < 0.0001
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focused on integrins that are known to bind ECM, espe-
cially, BM components controlling cellular adhesion.
Integrins act as anchors by linking the matrix with the
intracellular cytoskeleton, while availability of ECM
binding sites, i.e. ECM composition and density, has
been shown to regulate integrin clustering [33]. In com-
parison to mock controls, protein level of β3 integrin
was increased by 32% and of β1 integrin by 127% in
ΔpBK-ITIH5 clones (Fig. 5a and b) thus hypothesizing
that ITIH5 expression modulates activation of down-
stream effectors of the integrin signaling cascade cross-
talk like small G-proteins of the Rho subfamily.
Activation of the antagonists Rac1 and RhoA was ana-
lyzed which has been reported to regulate different steps
during cell movement and is thought being modulated
by β1 and β3 integrin, respectively [34]. Interestingly, we
found that the balance between the activity of RhoA and
Rac1 shifted towards increased activation of RhoA in
ITIH5 clones while Rac1 was abundantly activated in
control cells (Fig. 5c and d).
Consequently a closer look on mesenchymal migration
was taken by performing a wound healing assay. Forced
ITIH5 expression inhibited cell migration of basal-type
MDA-MB-231 cells, i.e. MDA-MB-231 mock clones
repopulated the wounded area notably faster than corre-
sponding ITIH5-expressing single-cell clones over 4 days.
Impairment of MDA-MB-231 cell migration was con-
firmed by all analyzed MDA-MB-231 ITIH5 single-cell
clones (n = 5) compared to the MDA-MB-231 WT and
mock clones (n = 3). The mean cell motility rate of inde-
pendent clones of both groups is shown in Fig. 5e.
ITIH5-expressing clones were not able to detach from
the peripheral edge of the confluent cell layer and to mi-
grate as single-cells into the wound as shown for mock
clones (Fig. 5f ). Already 1 day after scratching, most
mock clones had repopulated almost the entire wound
(overall 86.3%), whereas the MDA-MB-231 ITIH5 clones
covered on average 43.6% of the wounded area (Fig. 5g).
Interestingly, ITIH5 expression did not alter the migra-
tion of T47D ΔpBK-ITIH5 single-cell clones (data not
shown) whose parental cell line is known to feature
already a well-differentiated, epithelial-like phenotype.
Given that, the architecture of the actin cytoskeleton
and focal adhesions was determined reflecting integrin
clusters on the cell surface of MDA-MB-231 ITIH5 cells.
24 h after seeding ITIH5-expressing MDA-MB-231 cells
formed cell clusters whose focal adhesions were found
being close to the cell periphery and were less elongated.
In contrast mock single-cells exhibited F-actin stress fi-
bers passing through the cell body that are connected
with elongated focal adhesion sites in the cell body
(Fig. 5h). MDA-MB-231 ITIH5 clones showed less stress
fiber formation but formed mostly cortical actin bundles,i.e. the F-actin is condensed around the cell periphery.
As expected for those tightly organized cell clusters,
single-cell polarization was impaired, i.e. cell polarization
into a distinct protrusive front and a retracting rear as
obvious in mock cells (illustrated in Fig. 5i). Instead,
ΔpBK-ITIH5 cells remained in a tight cell cluster poten-
tially connected by cell-cell contacts as upregulation of
desmosomal cadherins was demonstrated. Real-time
PCR analysis significantly confirmed increased expres-
sion of desmoglein-2 (DSG2, array-effect: FC: 2.04) by
7.2-fold, of desmocollin-2 (DSC2, array-effect: FC: 1.54)
by 184.0-fold and of desmoplakin (DSP, array-effect: FC:
1.91) by 24.8-fold (Fig. 5j).
ITIH5-driven phenotype switch of basal-type breast
cancer cells is associated with epigenetic reprogramming
Facing the identified phenotype switch of aggressive
breast cancer cells driven by ITIH5 expression, we fo-
cused on potential mechanisms. It has been suggested
that cellular differentiation might impact on epigenetic
regulation of gene expression [35]—particularly on DNA
methylation [36–38]. Therefore, DNA methylation pro-
files of the MDA-MB-231 WT, mock (#1 and #2), and
ITIH5 single-cell clones (#4, #7, and #12) was analyzed
using the Infinium HumanMethylation450 (450 K) Bead-
Chip technology. We then selected those CpG sites with
significant (p < 0.05) methylation differences (mean β-
value) of more than 20% between mock (and WT) and
ITIH5-expressing MDA-MB-231 clones: overall 1511
CpG sites passed this threshold (Fig. 6a) corresponding
to 728 different genes. 695 of these genes are associated
with a GO term including in particular those genes in-
volved in cellular adhesion (e.g. GO:0098742, p = 2.98 ×
10−12) (Fig. 6b). Interestingly, these GO terms were
nearly conformable with the GO annotations based on
mRNA expression profiling (see Table 1). In addition
highly significant enrichment of genes encoding for
cellular components of the ECM (e.g. GO: 004442,
p = 4.68 × 10−4) was found including collagens such as
COL2A1 or COL15A1. Using gene set enrichment ana-
lysis (GSEA) the most significant overlap was observed
of hypo- and hypermethylated CpG sites located in a
promoter region (TSS1500, TSS200, 5’UTR) (overall
n = 404) with genes, for instance, 1) containing around
the TSS the motif CAGGTG which matches annotation
for TCF3 (p = 2.26−20), or 2) targeted by the Polycomb
(PcG) protein SUZ12 (p = 1.66−15) (Additional file 2).
Subsequently, hyper- and hypomethylated CpGs iden-
tified in ITIH5-expressing MDA-MB-231 clones were
compared with a list of genes of embryonic stem cells
(ES) that have H3K4Me3 and/or H3K27Me3 enrichment
in a 5000 bp region upstream and downstream from the
transcription start site (TSS) based on previously pub-
lished ChIP-seq data [39]. The methylation status was
Fig. 5 ITIH5 alters integrin signaling impairing single-cell polarization. a Integrin protein expression/stability in ITIH5 and mock clones. β -actin served as
loading control. b Densitometric evaluation of western blot results demonstrating an integrin protein shift. Relative protein expression levels are normalized
to β-actin. Mean protein level of mock clones was set to 100%, respectively. c Analysis of integrin downstream signaling. Representative western blot results
illustrate activated Rac1 and RhoA GTPases in two independent ITIH5 and mock clones. Total Rac1 and RhoA served as loading control. d Densitometric
evaluation of GTPases activation. Relative protein expression levels are normalized to total Rac1 and total RhoA, respectively. Mean protein level of mock
clones was set to 100%. e Cell migration was analyzed by using a wound healing assay. Mean migration rate of a control cell set (n= 4, WT and mock
clones) and ITIH5 MDA-MB-231 clones (n= 4) was analyzed over 4 days. Vertical lines: standard deviation (S.D.) of triplicates. Cell-free area on day 0 was set
as 100% and used for standardization. Δday1: differences of cell-free areas on day 1. f Documentation of the wounded area by SEM 24 h after scratching. Left
rectangle regions: separately enlarged. Scale bar = 100 μm. g Detailed comparison of wound closure after 24 h for each single-cell clone. h Visualization of
F-actin architecture and focal adhesion are shown of ITIH5 and mock clones. Upper rows: Representative micrographs of ITIH5 clone #7 and ITIH5 clone #4.
White arrows indicate cortical actin bundles (red) and less elongated focal adhesions (green dots). Lower row: Representative micrographs of mock clone #1.
White arrows: F-actin stress fibers (red) co-localized with elongated focal-adhesion sites (green) in the cell body of single-cells. Scale bar = 10 μm. i Illustration
of the ITIH5-associated impact on cell-polarization necessary for cell migration. a: ITIH5 clones showed tight clusters lacking cell polarization. b: mock cells
are able to form a distinct protrusive front and a retracting rear. Scale bar = 10 μm j Real-time PCR analysis demonstrating significant upregulation of DSP,
DSC2 and DSG2 in ITIH5 (n= 5) compared to mock clones (n= 4). Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines: range, peak and
minimum; *p< 0.05, **p< 0.01, ***p< 0.001
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Fig. 6 Epigenomic reprogramming of genes involved in cell adhesion and proliferation triggered by ITIH5 expression. Analysis of the DNA
methylation profiles of the MDA-MB-231 WT, mock (#1 and #2), and ITIH5 transfected MDA-MB-231 ITIH5 single-cell clones (4, 7, and #12) using
the Infinium Human Methylation450 (450 K) BeadChip technology. a Heatmap of 1512 CpG sites exhibiting significant (p < 0.05, Δβ-value > 0.2)
methylation alterations between MDA-MB-231 WT, mock and ITIH5 single-cell clones demonstrated an epigenetic reprogramming of MDA-MB-231
cancer cells. b Cartoon illustrating gene ontology analysis of annotated 695 genes corresponding to the 1511 CpG sites. c Heatmap analysis of 242
hyper- or hypomethylated CpG sites (out of identified 1511 CpGs) located in potential regulatory promoter regions that are associated with H3K4Me3
and/or H3K27Me3 enrichment in a 5000 bp region upstream and downstream from the TSS. Chromatin status: K27 = H3K27Me3, K4 =H3K4Me3
Rose et al. Molecular Cancer  (2017) 16:44 Page 10 of 22determined in 14,356 promoter regions characterized by
Ku and colleagues comprising a minimum of 5 CpG
sites (Additional file 3). 274 CpG sites out of 1511 were
classified according to 242 different corresponding pro-
moter regions (Fig. 6c, Additional file 4). 214 promoters
featured a significant (p < 10−6) association with a poten-
tial H3 methylation status described for ES cells. Inter-
estingly, regions associated with the potential PcGsignature H3K27Me3 were significantly enriched by 3.3-
fold (Table 2) in MDA-MB-231 ITIH5 clones. Promoters
with a combined, i.e. with a potentially bivalent,
H3K4Me3 and H3K27Me3 status were also enriched by
1.9-fold whereas regions associated with a potential
H3K4Me3 status were under-represented in this data
set. Hence, the identified epigenetic shift caused by
ITIH5 involves promoters potentially associated with
Table 2 Enrichment of differently methylated promoter regions
potentially harboring histone H3 modifications described by







K4 9118 124 (1.36%) 0.71
K27 140 9 (6.43%) 3.34
K4 + K27 2176 81 (3.72%) 1.93
None 1130 28 (2.48%) 1.29
Total 12,564 242 (1.93%)
* p < 10−6 according to Fisher’s exact test
Table 3 Genes 3-fold up-/downregulated by ITIH5
Symbol Fold-change Parametric p-value Regulation
TNS4 0.13 0.0121 down
CHRDL1 0.21 0.0306 down
AREG 0.22 0.0166 down
AGR2 0.23 0.0169 down
GLB1L2 0.26 0.0455 down
TMEM163 0.29 0.0237 down
ZG16B 0.32 0.0139 down
TPTE 3.45 0.0114 up
NDRG2 4.29 0.0002 up
GJA5 4.34 0.0384 up
GALNT14 4.44 0.0011 up
DAPK1 4.55 0.0485 up
COX7B2 5.05 0.0094 up
PLCB4 5.55 0.0047 up
GMFG 6.51 0.0377 up
THY1 8.31 0.0089 up
ENG 9.00 0.0019 up
LCP1 14.83 0.0121 up
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restoration and/or silencing of gene expression.
DNA demethylation of distinct promoter regions is
associated with re-expression of the tumor suppressor
gene DAPK1
We hypothesized that the identified shift in DNA methy-
lation pattern influences expression of genes contribut-
ing to the ITIH5 induced, tumor suppressive phenotype
of MDA-MB-231 cells. Therefore, we had a closer look
on the gene expression pattern associated with ITIH5.
By applying a class comparison analysis between control
cell populations (mock clones) and ITIH5-transfected
clones, we aimed at identifying the strongest co- and
anti-regulated genes which met the following criteria:
Significantly (p < 0.05) differentially expressed with a
minimal change in expression by 3-fold. Significantly
up- and downregulated genes are summarized in Table 3.
While tumor promoting genes such as AGR2 were
downregulated, known tumor suppressor genes like
NDRG2 and DAPK1 were upregulated 4.3- and 4.6-fold,
respectively.
DAPK1 expression was furthermore verified on mRNA
as well as on protein level in ΔpBK-ITIH5 breast cancer
cells (Fig. 7a). By comparing the profiled DNA methyla-
tion of significant CpG sites and the expression signa-
ture, a clear demethylation of CpG sites within the 5’
UTR region close to the transcription start site (TSS) of
the DAPK1 gene in ΔpBK-ITIH5 clones (Fig. 7b) was
shown. Within this upstream promoter region (ENSEMBL
contig ENSG00000196730) a CpG-rich island between
genomic positions 90,112,413 and 90,114,138 (+270 bp to
+1725 bp relative to the expected TSS) on chromosome
9q was verified which met the following criteria according
to Li et al. [40]: DNA region: ≥200 bp; Obs/Exp: ≥0.6;
%GC: ≥50. This promoter region corresponds to the 242
identified promoters showing a significantly altered
methylation status and is potentially marked by an activat-
ing H3K4Me3 histone modification (see Additional file 4).
Performing Genomatix data base analysis [41] putative
transcription binding sites in this 5’UTR locus weredetermined with highly statistical reliability, namely
SP1F (matrix similarity: 0.941), SMAD (matrix simi-
larity: 0.963) and TF2B (matrix similarity: 1.0). In
contrast to the 5’UTR region, CpG sites located
within the DAPK1 gene body were clearly hyper-
methylated when compared to mock control clones
(Fig. 7b).
By performing both methylation-specific PCR (MSP)
(Fig. 7c) and pyrosequencing (Fig. 7d to e) decreased
methylation level within the CpG island closely associ-
ated to the TSS of DAPK1 was subsequently confirmed.
Based on pyrosequencing the methylation status of 14
individual CpG sites was analyzed demonstrating com-
pletely hypomethylated CpG sites within the 5’UTR re-
gion of DPAK1 in ΔpBK-ITIH5 cells. The median
DAPK1 methylation level of ΔpBK-mock clones (n = 3)
was 26% featuring a high range between 12.5 and 50.5%,
whereas the median methylation of ITIH5 clones (n = 4)
was consistently decreased in all analyzed ITIH5-
expressing clones (n = 4) down to 1% (mean: 1.3%, s.d. ±
1.4%; range 0.0–1.5%). Overall DAPK1 methylation was
decreased in median by 96.8% (Fig. 7e).
Next, decreased DAPK1 promoter methylation was
demonstrated 72 h after application of demethylation
drugs to mock control cells (clone #2). The median
methylation level of the analyzed DAPK1 5’UTR re-
gion was reduced from 67 to 53% (Fig. 8a to b) in
mock controls over 3 days. A representative diagram
illustrating the methylation level of all 14 analyzed
CpGs in mock cells, before and after DAC and TSA
Fig. 7 ITIH5 mediates demethylation of the DAPK1 promoter 5’UTR region leading to its re-expression in basal-type breast cancer cells. a DAPK1
re-expression was confirmed in ITIH5 clones (n = 4) by real-time PCR (upper graph) and western blot analysis (lower images) when compared with
and mock clones (n = 3) and MDA-MB-231 WT. β-actin served as loading control. b Schematic map of the human DAPK1 gene including the
relative positions and β-values of CpG dinucleotides measured by 450 K methylation array profiling in MDA-MB-231 WT cells, mock and ITIH5
single-cell clones. Red: high methylation, blue: low methylation. +1: DAPK1 transcription start site (TSS). A predicted CpG island is located between
genomic positions 90,112,413 and 90,114,138 (+270 bp to +1725 bp relative to the expected TSS) within the 5’-UTR region. At this site a potential
activating H3K4Me3 (K4) histone modification as mapped by Ku et al. [41] was described. The relative positions of 18 CpG sites analyzed either
by MSP (used primer: black arrows) and / or pyrosequencing within the DAPK1 5’UTR region are indicated. Three putative transcription binding
sites in this gene locus were statistically identified: SP1F (matrix similarity: 0.941), SMAD (matrix similarity: 0.963) and TF2B (matrix similarity: 1.0).
c DNA methylation of the DAPK1 5’UTR locus verified in mock and ITIH5 single-cell clones by using MSP. Band labels with U and M represent
an unmethylated and methylated DNA region, respectively. Bisulfite-converted unmethylated, (U-co) and polymethylated, genomic (M-co) DNA
were used as controls. NTC: non-template control. d-e Quantification of DAPK1 5’UTR DNA methylation frequency by using pyrosequencing.
d 3D graph illustrates methylation level for each analyzed CpG site (overall 14 CpGs) within the DAPK1 5’UTR locus in mock (n = 3) and ITIH5
(n = 4) single-cell clones. e Box plot analysis demonstrates significant reduction of the median methylation ratio within the DAPK1 5’UTR region in
ΔpBK-ITIH5 compared to ΔpBK-mock clones. Horizontal lines: grouped medians. Boxes: 25–75% quartiles. Vertical lines: range, peak and minimum;
*p < 0.05, **p < 0.01, ***p < 0.001
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the reduced methylation level, upregulation of
DAPK1 mRNA expression was observed in mock
tumor cells after demethylation treatment (Fig. 8c)
whereas no further DAPK1 expression was shown in
ITIH5 clone #4 harboring already an unmethylatedDAPK1 promoter region as shown in Fig. 7d. In
mock control cells, only treatment of both DAC and
TSA leads to a maximum of DAPK1 mRNA re-
expression by more than 1500-fold. These findings
support our notion that epigenetic alterations of the
DAPK1 promoter may be caused by synergistic
Fig. 8 In vitro demethylation of the DAPK1 5’UTR locus correlates
with DAPK1 re-expression in ΔpBK-mock cells. a Pyrosequencing
analysis for each CpG dinucleotide (1–14) within the DAPK1 5’UTR
region determined prior (−DAC/-TSA; dark-grey-filled) and after
in vitro demethylation treatment (+DAC/+TSA; grey-filled). b Box plot
analysis shows reduction of the median methylation ratio within the
DAPK1 5’UTR region in ΔpBK-mock cells after DAC/TSA treatment (+)
compared to non-treated cells (control). Horizontal lines: grouped
medians. Boxes: 25–75% quartiles. Vertical lines: range, peak and
minimum; **p < 0.01. c Real-time PCR results illustrate a clear DAPK1
re-expression after treatment with both DAC and TSA (+) in mock
clones while now further expression of DAPK1 mRNA was detected
in ITIH5 clones already harboring an unmethylated DAPK1 5’UTR
region. Non-treated cells (-DAC,-TSA) were set to 1, respectively.
Error bars: + s.e.m
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modification that has a major impact on the regula-
tion of DAPK1 re-expression.
Knockdown of DAPK1 promotes tumor cell migration in
MDA-MB-231 ΔpBK-ITIH5 cells
As DAPK1 (death-associated protein kinase (DAP
Kinase)) is a well-known tumor suppressor [42], we aimed
to demonstrate whether its re-expression may explain
some of the ITIH5-associated suppressive attributes in
basal-type breast cancer cells. DAPK1 has been shown to
mediate apoptosis but accumulating studies showed in-
volvement of DAPK1 in integrin signaling impairing cell
migration [43]. RNA interference-mediated DAPK1
knockdown was performed in ITIH5-expressing MDA-
MB-231 cells (clone #7) applying two different siRNA se-
quences (#1 and #2) alone as well as in combination
(Fig. 9a and b). Interestingly, based on a caspase 3 activity
assay, a clear apoptotic resistance of transfected cells was
not observed after DAPK1 knockdown (data not shown)
that is consistent with a previous report in this cell line
[44]. In turn, using a monolayer wound healing assaysiRNA-mediated knockdown of DAPK1 clearly increased
tumor cell migration of ΔpBK-ITIH5 clone #7 compared
to corresponding cells transfected with the non-silencing
control siRNA (nc-control siRNA) that served as negative
control (Fig. 9c and d). Stably ITIH5-expressing MDA-
MB-231 cells transfected with both DAPK1 siRNA se-
quences nearly repopulated the entire wounded cell-free
area (siRNA #1: 100%, siRNA#2: 89.71%, siRNA #1+ #2:
96.35%) after 48 h, i.e. ΔpBK-ITIH5 cells with reduced
DAPK1 expression tend to restore motile characteristics
as observed for MDA-MB-231 WT cells (see Fig. 5g). In
contrast to that, nc-control siRNA transfected ITIH5-
expressing clones had repopulated only 67.01% of the
wound area at this time point. These data clearly demon-
strate that the ITIH5-DAPK1 molecular axis plays an im-
portant role in the regulation of MDA-MB-231 cell
motility.
Discussion
Previously, we revealed that loss of ITIH5 expression
caused by aberrant promoter hypermethylation is associ-
ated with poor prognosis and clinical correlates of
metastasis in breast cancer [16, 23]. In the current study,
ITIH5 downregulation was abundantly found in distant
metastases and intrinsic subtypes associated with poor
prognosis, i.e. luminal B, HER2-enriched and basal-like
breast cancer. ITIH5 loss predicted shorter overall sur-
vival of patients with non-metastatic tumors proposing a
prominent role of ITIH5 especially in tumors which tend
to metastasize early and whose disease management and
personalized therapy is still insufficient. To give insight
into ITIH5 biology going beyond the assumed role as a
prognostic biomarker in breast carcinomas, we estab-
lished two different stable gain-of-function models, i.e.
weak-aggressive T47D and metastatic MDA-MB-231
single-cell clones overexpressing full-length ITIH5. In
both cell lines ITIH5 mediated suppression of colony
and cell growth while only in luminal-type T47D cells
ITIH5-triggered increased programmed cell death. How-
ever, this is consistent with our recent finding in
luminal-like RT112 bladder cancer cells due to ITIH5
re-expression [18]. These data indicate that ITIH5 may
control mechanisms to reduce cancer cell growth inde-
pendently of a given tumor subtype or entity similar to
the described function of ITIH1-3 by stabilizing ECM
integrity [9, 45, 46].
In MDA-MB-231 breast cancer cells ITIH5 induced a
phenotypic switch, which to our knowledge has not yet
been reported for any member of the ITI protein family
before. Originally metastatic cancer cells underwent an
epigenetic shift driven by ITIH5 that cause a distinct sig-
nature of expressed genes. Among others, re-expression
of known tumor suppressor genes such as DAPK1 [42]
was clearly demonstrated. As a consequence, forced
Fig. 9 DAPK1 knockdown restore a motile phenotype in ΔpBK-ITIH5 cells in vitro. a DAPK1 protein expression in ITIH5-expressing cells 48 h after
transfection with DAPK1-siRNA #1, DAPK1-siRNA #2 as well as #1 and #2 combined in comparison to nc siRNA transfected control cells. β-actin
served as loading control. b Densitometric determination of DAPK1 protein knockdown in ΔpBK-ITIH5 cells compared to control. c Cell migration
of ITIH5 clones after treatment with DAPK1-siRNAs was analyzed by using a wound healing assay over 72 h. nc siRNA transfected cells served as
negative control. Vertical lines: standard deviation (S.D.). Cell-free area on day 0 was set as 100% and used for standardization. d Representative
wound area documentation by light microscopy of DAPK1-siRNA #1 and nc siRNA control 0, 12, 36, and 60 h after scratching. White line: cell-free
wound area. White dashed line: original wound area size at 0 h. Scale bar: 500 μm. e Working model highlighting factors potentially involved in
ITIH5-driven phenotype shift of mesenchymal MDA-MB-231 breast cancer cells towards an epithelial-like state. ITIH5 remodels the ECM that is
accompanied by changes in integrin composition. As a consequence downstream signaling is shifted towards RhoA activation. Clustered cancer
cells further lacked polarization but featured in turn strong cell-matrix adhesion and modulated biomechanical cues. Re-expression of DAPK1,
caused by epigenetic reprogramming, may be finally involved in ITIH5 mediated suppression of tumor cell migration dynamics potentially by
re-organization of cytoskeleton structures as recently described (1): [43, 44]
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phenotype causing a reduction of lung colonies in vivo.
As metastases were almost exclusively found in lungs of
mice injected with cancer cells lacking ITIH5 expression,
impaired tumor initiation capabilities could be sug-
gested, a feature mainly attributed to CSC.
Mechanistically, ITIH5 expression was associated with
regulation of genes involved in categories of cell adhe-
sion and cell differentiation. Matrix adhesion of ΔpBK-
ITIH5 cells was significantly enhanced on physiologically
coated substrates, mimicking the basement membrane
(BM). ITIH5 also altered the composition of such spe-
cialized ECM structures as the BM constituent collagen
type IV was identified being upregulated. According to
this, profound changes in expression of integrin cellsurface receptors were demonstrated that are known
to bind to the BM being involved in controlling cell
adhesion and migration [34, 47]. Because of their
outside-in-signaling capacity, integrins function not
only as regulators of cell adhesion but also as sensors
of their extracellular environment regulating down-
stream signaling [48] and it is likely that they have
completely different effects on behavior of cancer
cells, depending on which integrin receptors and
ligands are exposed [49]. Alterations in the profile of in-
tegrin expression as identified in ITIH5 clones have been
reported to cause dramatic shifts in modes of cell
migration [34]. In particular the balance between β1, a
putative metastasis suppressor in human cancer [50], and
β3 integrin is thought to play a critical role [51].
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to ITIH5 re-expression in MDA-MB-231 cells. Never-
theless, β1 integrin, which is almost not expressed in
mock clones, is even stronger induced in ITIH5 clones
so that the balance between β3 and β1 integrin was
clearly shifted towards β1. While β3 integrin has been
reported being associated with Rac1 activation, β1 in-
tegrin regulates in particular RhoA activity [34]. This
notion is important because Rac1 facilitates F-actin
polymerization and locally decreases cell-membrane
tension that lead to lamellipodia formation during the
first step of cell migration. Its activity is blocked by
RhoA GTPases in the second phase of cell migration
regulating actomyosin contractility [52].
Already in 2005, Danen et al. reported that integrin
αVβ3 promotes directional cell migration in the absence
of integrin α5β1 being characterized by a single large
lamellipodium and lower RhoA activity [53, 54] as also
obvious in mock control cells. In turn, α5β1 is particu-
larly efficient at promoting later phases of cell spreading
by supporting strong RhoA-mediated contractility and
random migration. In our ΔpBK-ITIH5 model we
showed that ITIH5-expressing MDA-MB-231 cells were
not able to disseminate from neighboring cells moving
as single-cells directional into the wounded area. As a
consequence ITIH5-expressing significantly higher con-
tractile cell forces compared to their mock clones. This
result is in good agreement with the simultaneous up-
regulation of active RhoA-GTPases in ITIH5 clones,
which are known to mediate matrix adhesion-
dependent cell forces via Rho/Rock signaling cascades
[55] giving a mechanistic explanation for the high-
adhesive, well-differentiated phenotype. These findings
were associated with clustering of ΔpBK-ITIH5 cells
and with reduced polarization into a distinct protru-
sive front and a retracting rear end. Truong et al.
have recently reported that functional inhibition of β1
integrin converted the migratory behavior of human
triple-negative breast cancer (TNBC) cells from col-
lective to single-cell movement facilitating lung
colonization in vivo [56]. Moreover, β1 integrin pro-
motes an epithelial phenotype in those TNBC cells by
restoring, for instance, E-cadherin expression in a
TGF-β dependent manner. Hence, upregulation of
desmosomal components like DSP and DSC2 linking
neighboring cells may contribute to tightly organized
colony structures of ITIH5-expressing MDA-MB-231
cells impairing mesenchymal single-cell migration.
It is astonishing that expression of a single ECM factor
in vitro, i.e. ITIH5, can effect hyper- or hypomethylation
of more than 1500 CpG sites in metastatic cancer cells.
The term “epigenetic reprogramming” is commonly used
to describe profound alterations in the epigenetic
makeup (e.g. [57, 58])—and therefore appears to bejustified in this context. Addressing the question why
those DNA regions showed differences in DNA methyla-
tion, we focused on mechanisms known to be involved
in regulating DNA methylation dynamics. So far increas-
ing evidence suggest that histone modifications, namely
H3K27Me3 and H3K4Me3, and associated PcG and
trithorax-group (trxG) proteins are not only critical for
changes in gene expression upon embryonal stem (ES)
cell differentiation [59], but also for development of can-
cer (stem) cells [60–63]. Cross talk between histone
methylation marks and DNA methylation is thought to
regulate DNA methylation dynamics via recruiting pro-
teins like DNA methyltransferases (DNMTs) [64]. In
agreement with that, GSEA analysis revealed highly
significant enrichment of genes harboring targets of the
Polycomb protein SUZ12. By correlating corresponding
CpG positions with histone modification marks as
described by Ku et al. [39], 214 promoters were identi-
fied that have been previously reported being marked by
either H3K4Me3 and/or H3K27Me3 in ES cells and have
changed their DNA methylation status in ITIH5 clones.
Importantly, genes associated with both H3K27Me3
alone and a combined, i.e. with a potentially bivalent
H3K4Me3 and H3K27Me3 status, were significantly
overrepresented. Thus, enrichment of promoter regions
associated with dynamics in H3 methylation could in-
deed contribute to the epigenetic shift allowing distinct
DNA demethylation patterns as observed for the DAPK1
5’UTR sequence close to the TSS.
DAPK1 is a calmodulin-regulated and cytoskeleton
associated serine/threonine kinase [65, 66]. Accumu-
lating evidence suggest that DAPK1 plays an import-
ant role in tumor suppression. Epigenetic silencing of
DAPK1 has been demonstrated to correlate with
higher risk for recurrence and metastasis in various
tumor entities [42]. DAPK1 is a pro-apoptotic factor
(e.g. [67]) that abrogates matrix survival signals by
inside-out inactivation of β1 integrin impairing the
p53-apoptosis pathway [68]. Aside of its apoptotic
function Kuo and colleagues postulated an apoptosis-
independent mechanism of DAPK1, i.e. uncoupling of
stress fibers and focal adhesions by modulation of in-
tegrin adhesion [43]. This study fits to our observa-
tion that the cytoskeleton was re-organized in
DAPK1-expressing ΔpBK-ITIH5 cells. It has been
shown that DAPK1 mediates a disruption of the cell
polarity by blocking the Rho-GTPases cdc42 in MDA-
MB-231 cells leading to inhibition of cell migration in
a wound healing assay [44]. Consistent with that,
knockdown of DAPK1 had restored motile capacities,
at least in part, of ITIH5-expressing MDA-MB-231
cells, indicating involvement of DAPK1 in the RhoA-
β1-integrin-mediated signaling axis. A cartoon sum-
marizing these finding is illustrated in Fig. 9e.
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by ITIH5 in basal-type breast cancer cells and the puta-
tive role of specific ECM components and receptors
appear complex, and must be addressed in future stud-
ies. As luminal T47D cells already grow in epithelial-like
clusters, it makes sense that ITIH5 did not trigger a simi-
lar effect in those already well-differentiated tumor cells.
Beyond that different settings of cell-surface receptors
might explain a responsibility for ITIH5-mediated func-
tions such as HA-crosslinking in dependence of a given
background. For instance, MDA-MB-231 cells highly ex-
press CD44, a known HA-receptor facilitating metastatic
CSC-like features [69], whereas T47D has been previously
characterized as CD44low [70]. Since Mina Bissell postu-
lated a profound impact of the ECM and regulatory pro-
teins on cell differentiation [1] already in 1982 [71], it is by
now well described that epigenetic gene expression con-
trol such as chromatin remodeling [2, 72] can be orches-
trated by signals from the cellular microenvironment.
Biomechanical cues as modified by ITIH5 are thought
to contribute to global internal organization of nuclei
[73, 74] controlling chromatin structure [36]. Irrespective
of that our data underline the complex but fundamental
effects of the ECM and its constituents on cell phenotypes
and differentiation in the context of malignant
progression.
Conclusions
In the current study, we provide evidence that the ECM
modulator ITIH5 suppresses tumor cell migration and
colonization of metastatic MDA-MB-231 breast cancer.
As a result of an epigenetic reprogramming driven by
ITIH5, tumor suppressor genes such as DAPK1 were re-
expressed reversing the aggressive phenotype. Bearing in
mind that MDA-MB-231 cells have been shown display-
ing CSC properties [75, 76], the shift of ITIH5-
expressing MDA-MB-231 cancer cells towards an
epithelial-like differentiation state accompanied by an
inability to initiate high number of metastases in vivo
suggests impairment of metastatic characteristics.
Methods
Animals
Female BALB/cnu/nu mice were purchased from Charles
River Laboratories International (Wilmington, MA). All
animal procedures and experiments were conducted in
accordance with the German federal law regarding the
protection of animals. The respective protocols were
approved by the administration of the “Landesamt für
Umwelt, Natur und Verbraucherschutz” (LANUV,
Recklinghausen, Germany - AZ 87-51.04.2010.A226). For
the care of laboratory animals, Guide for the Care and
Use of Laboratory Animals (National Institutes of Health
publication 86-23, 1985 revision) was followed.TCGA data set
Data from breast cancer, normal and metastatic tissues
were used from The Cancer Genome Atlas (TCGA) [25],
comprising overall patients’ data of an independent plat-
form: Gene expression IlluminaHiSeq (n = 1215). The data
of this study can be explored using the cBio Cancer
Genomics Portal (http://cbioportal.org).
Cell lines and reagents
Breast cancer cell lines T47D and MDA-MB-231 were
obtained from the American Type Culture Collection
(ATCC, Manassas, VA), which assures molecular
authentication of cell] lines [77], and was resuscitated
before using in experiments. Otherwise cell lines were
authenticated, within 12 months of being used in the
study and were cultured as described previously [78] and
regularly tested for mycoplasma infection using the
PCR-based Venor® GeM Mycoplasma Detection Kit
(Minerva Biolabs, Berlin, Germany).
Transfection and single-cell cloning of T47D and
MDA-MB-231 cells
Transfection of both T47D and MDA-MB-231 cells with
ITIH5-pBK-CMV expression vector, containing the full-
length human ITIH5 cDNA derived from normal breast
tissue, was performed as recently described [16]. Single-
cell clones were selected by limited dilution under genet-
icin (G418) pressure (T47D: 400 μg/ml; MDA-MB-231:
1000 μg/ml).
RNA interference of DAPK1
Human ΔpBK-ITIH5 and mock clones were transfected
with HiPerfect transfection reagent (Qiagen) applying
two siRNA sequences directed against DAPK1 alone (#1:
Hs_DAPK1_6, Cat. No. SI02223781, 5’-CGGCTATTA
CTCTGTGGCCAA -3’ and #2: Hs_DAPK1_6, Cat. No.
SI02223774, 5’- AAGCATGTAATGTTAATGTTA.-3’
(20 nM each)), or in combination of both according to
the manufacturer’s instructions. Cells were treated every
48 h with siRNA sequences to ensure sufficient DAPK1
knockdown. Commercial non-silencing control siRNA (nc
siRNA) (5’-AATGCTGACTCAAAGCTCTG-3’) served as
negative control. Knockdown was verified by RT-PCR and
western blot analysis after 48, 96 and 144 h. Functional
studies were started immediately after 48 h siRNA
treatment.
Nucleic acid extraction and reverse transcription PCR
Total cellular RNA from cultured cells and tumor nod-
ules of mice lungs (samples pooled for test group) was
prepared by using TRIzol reagent (Invitrogen). cDNA
was synthesized using the reverse transcription system
(Promega, Madison, WI) as previously described [16].
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cDNAs were amplified by real-time PCR using SYBR-
Green PCR mix (Bio-Rad Laboratories, Munich,
Germany) performed in an iCycler IQ5 (Bio-Rad Labora-
tories) and quantified by the comparative CT method
calculating relative expression values as previously
described [79]. All used primers spanned at least one
intron, and are listed in Additional file 5.
In vitro demethylation
Whole-genome demethylation of human stable MDA-
MB-231 clones was performed as recently published
[80]. In brief, demethylation agent 5-aza-2’-deoxycyti-
dine (DAC) was added to a final concentration of
5 μM on days 1, 2 and 3. On day 3 cells were
additionally treated with 300 nM trichostatin A (TSA)
(Sigma-Aldrich). Cells were harvested on day 4 for
RNA and DNA extraction.
Bisulfite-modification and methylation-specific PCR (MSP)
Bisulfite conversion and MSP reaction conditions of
in vitro derived DNA was performed as specified previ-
ously [81]. For used DAPK1 MSP primers and cycle
conditions see Additional file 6.
Pyrosequencing
Pyrosequencing of 14 CpG sites within the DAPK1
5’UTR region was performed by using the PyroMark
PCR Kit (Qiagen) for initial fragment amplification. The
PyroMark96 ID device and the PyroGoldSQA reagent
Kit (Qiagen) were used as previously described [18]. The
DAPK1 assay was designed by using the Pyromark Assay
Design Software (Qiagen) and all primers are listed in
Additional file 7.
GTPases pulldown
Activation of both Rac1 and RhoA was measured by
using the Active Rac1 Detection Kit (#8815, Cell Signal-
ing, Danvers, MA, USA) and the Active Rho Detection
Kit (#8820, Cell Signaling) respectively, according to the
manufacturer’s instructions. In brief, single-cell ΔpBK-
ITIH5 and mock clones were cultured in G418 contain-
ing growth medium for 48 h. Subsequent to the cell
lysis, 550 μg of total cell protein lysate for each clone
was mixed with 20 μg of GST-PAK1-PBD capturing
(active) RAC1-GTP or GST-Rhotekin-RBD for RhoA.
Glutathione matrix-immobilized Rac1-GTP or Rho-GTP
was eluted in SDS sample buffer supplemented with
DTT. After heat denaturation (5 min, 95 °C) Rac1 and
RhoA proteins were detected by western blot analysis
using specific antibodies (see Additional file 8). Total
cellular RAC1 or RhoA protein was determined for each
sample and used for normalization.Western blot
Western blot analysis was performed as previously
described [82] but slightly modified as following: Pro-
teins were extracted in RIPA lysis buffer, then separated
in 4–12% Bis-Tris gels (Invitrogen Life Technologies,
Darmstadt, Germany) under reducing (50 mM DTT)
conditions using MES-SDS running buffer and electro-
blotted onto nitrocellulose membranes (0.2 μm). Com-
mercial primary antibodies used are listed in Additional
file 8. The generated anti-ITIH5 antibody was previously
characterized [18]. Equal protein loading was monitored
by using β-actin specific antibody.Immunofluorescence
MDA-MB-231-ITIH5 ΔpBK-ITIH5 and mock clones
(3 × 104 cells/well) were plated onto 12 mm round
glass coverslips. After 24 h incubation, cells were
fixed with 4% paraformaldehyde (PFA) and 0.5%
Triton X-100 in cytoskeleton buffer (10 mM PIPES,
150 mM NaCl, 5 mM EGTA, 5 mM glucose, and
5 mM MgCl2, pH 7.0) for 10 min at room
temperature. Afterwards, cells were gently washed
twice with PBS and post-fixed with 4% PFA for
10 min at room temperature. Subsequently, cells were
washed thrice with cytoskeleton buffer. For vinculin label-
ing, cells were incubated with the monoclonal antibody
hVIN-1 (Sigma-Aldrich, Deisenheim, Germany) for
30 min at room temperature followed by Alexa 488-
conjugated goat anti-mouse IgG (Molecular Probes,
Eugene, OR). The actin cytoskeleton was labelled with
Alexa 594-conjugated phalloidin (Molecular Probes). Cov-
erslips were mounted in Prolong (Molecular Probes).
Specimens were observed using an Axiovert 200 micro-
scope (Zeiss, Jena, Germany) equipped with a Plan-
Apochromat 100×/1.40 NA oil immersion objective in
combination with 1.6× or 2.5× optovar optics. Images
were recorded with a cooled, back-illuminated CCD cam-
era (Cascade, Photometrics, Tucson, AZ) driven by IPLab
Spectrum software (Scanalytics Inc., Rockville, MD).Scanning electron microscopy
Cells were fixed in 3% glutaraldehyde (in 0.1 M Soer-
ensen’s phosphate buffer [13 mM NaH2PO4 × H2O;
87 mM Na2HPO4 × 2H2O; pH 7.4]) for at least 1 h,
then rinsed in 0.1 M Soerensen’s phosphate buffer.
Next, cells were dehydrated in a graded ethanol series
(30, 50, 70, 90, 3% × 100%) and critical-point-dried in
carbon dioxide (CPD 010, Balzers Union, FL). The
dried samples were fixed on SEM stubs and sputter-
coated with gold (SCD 030, Balzers Union), then ana-
lyzed with an ESEM XL 30 FEG (FEI Philips, Eindho-
ven, Netherlands) in high vacuum mode at an
accelerating voltage of 10 kV .
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Cell adhesion experiments were carried out as previously
described [79] with minor modifications: Six-well plates
were coated with HA (100 μg/ml; Sigma-Aldrich) or
Matrigel™ (10 μg/ml; Sigma-Aldrich) and cells (5 × 105
cells/well) were incubated to adhere on surface for
30 min at 37 °C. Attached cells were fixed with 70%
ethanol for 10 min and stained with 0.1% crystal violet.
After 20 min cells were exhaustively washed with water
and dried overnight. The dye was dissolved in 0.002%
Triton X-100 in 100% isopropanol and carried over into
a 96-well plate to measure the optical density at 590 nm
using an ELISA reader (SpectraMax 340; Molecular
Devices; CA).
Fabrication of silicone rubber substrates
Substrate preparation and characterization of elastomer
material properties (Young’s modulus and Poisson’s
ratio) were performed as previously described [83]. In
brief, cross-linked elastomeric silicone rubber was used
(Sylgard 184, Dow Corning), which is supplied as a two-
component kit consisting of base and cross-linker oil.
Both components were mixed at a ratio of 1:50 and
mixed with 5% (v/v) yellow-green fluorescent nanobeads
(0.2 μm diameter, FluoSpheres, Invitrogen). This pre-
polymer mixture was applied onto a micro-structured
silicon dioxide mold containing 500 nm high microdots
with an edge length of 2.5 μm and a lattice constant of
3.5 μm, to generate a regular bead layer within the
elastomeric substrate. The polymer layer was then cov-
ered by a glass coverslip. A defined layer thickness of
80 μm was produced by putting spacers between the
silicon surface and the coverslip. Pre-polymer mixtures
were heat cross-linked (60 °C) overnight and finally
displayed a Poisson’s ratio of 0.5 and a Young’s modulus
of 15 kPa. For cell culture, the silicon mold and spacer
were removed and glass bottom covered elastomer
substrates were glued to a 3.5 cm Petri dishes with
1.5 cm holes.
Traction force microscopy and cell force retrieval
Live cell analyses were performed at 37 °C and 5% CO2
(cell incubator XL2, Carl Zeiss, Germany) using an
inverted confocal laser scanning microscope (cLSM710,
Carl Zeiss, Germany), utilizing a 40× EC Plan-Neofluar
oil immersion objective (PH3, NA = 1.3, Carl Zeiss,
Germany). Images were taken using the imaging soft-
ware ZEN 2.1, Carl Zeiss Germany). Confocal micro-
graphs of the cells (phase contrast) and of yellow-green
fluorescent beads were taken using an argon ion laser
(488 nm) with a transmitted light detector and a 490–
530 nm bandpass filter, respectively. Cells were seeded
onto fibronectin-coated (20 μg/cm2) TFM substrates
48 h before measurement. Only well-adhered cells wereanalyzed. Traction forces applied by a single cell to an
elastic substrate of defined stiffness cause deformations
fields that were visualized by tracking fluorescent marker
beads in the substrate. From the displacement of these
particles cell forces were calculated. Substrate deform-
ation was captured in the presence of cells and substrate
relaxation was obtained after cell elimination by trypsini-
zation. Cell area force fields (AFF) were retrieved from
vector displacement fields (DVF) determined by correlat-
ing the nanobead displacement in the deformed and the
relaxed, cell-free elastomer. MatLab-based algorithms
were used for data processing as previously described
[29, 84].XTT cell proliferation assay
The XTT proliferation assay (Roche Diagnostics,
Mannheim, Germany) was used and performed as
previously described [16].Apoptosis assay
Activity of the effector caspases 3 and 7 in ITIH5 and
mock single-cell clones was analyzed by using the
Apo-One® Homogeneous Caspase-3/7 Assay (Promega,
Mannheim, Germany) according to the manufacturer’s
instructions. Briefly, cells (1.5 × 104) were seeded in 96-
cell culture wells and incubated overnight (20% O2, 5%
CO2, 37 °C). Afterwards, staurosporine (1 μM, Sigma-
Aldrich, Deisenhofen, Germany) was applied to induce
apoptosis. Fluorescence intensity was quantified by using
an ELISA plate reader (excitation: λ = 485 nm; emission:
λ = 577 nm).In vitro colony formation and migration studies
Colony formation assays were performed as previously
described [79]. In vitro motility was analyzed per-
forming a monolayer scratch wound assay as previ-
ously specified [85].In vivo metastasis assay
MDA-MB-231 cells (3 × 106) of the ITIH5 test set
(ΔpBK-ITIH5 clones) or the control set (ΔpBK-mock
clones) were intravenously inoculated into the lateral tail
vein of 7 week old female Balb/cnu/nu mice. After 50 days,
mice were μCT scanned, and then sacrificed. Lungs were
harvested, photographed with the Discovery V12 stereo-
microscope (Zeiss), analyzed with DISKUS software
package (Königswinter, Germany), formalin-fixed (10%)
and paraffin-embedded. H&E-stained sections from each
lung tissue as well as a further slide sectioned at 30 μm
increments in the vertical plane were examined by a
pathologist in a blinded manner to quantify the number
of micro-metastases.
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Whole-body scans of mice were performed using non-
invasive μCT. A gantry-based dual energy micro-
computed TomoScope 30s Duo (CT Imaging, Erlangen,
Germany) was used. Matched pairs of mice (n = 7 each)
were scanned 50 days after tumor cell injection and anaes-
thetized using a 1.5% isoflurane inhalation narcosis. Mice
were scanned both natively and after intravenous applica-
tion of eXIA™160 (Binitio Biomedical, Ottawa, Canada),
an iodine-based and radiopaque blood pool contrast
agent. Injected dose of 0.1 ml/20 g body weight was used
[86]. Images were reconstructed using a Feldkamp type re-
construction (CT-Imaging, Erlangen, Germany) generat-
ing a voxel size of 70 × 70 × 70 μm3. Subsequently, images
were analyzed using Amide [87]. 3D architecture was visu-
alized using Imalytics Preclinical software [88].
Gene expression profiling
Gene expression profiling of the ITIH5 test set (three in-
dependent MDA-MB-231 ΔpBK-ITIH5 clones) and the
control set (three independent MDA-MB-231 ΔpBK-
mock clones) was carried out by the IZKF Chip-Facility
(Interdisciplinary Centre for Clinical Research Aachen
within the Medical faculty of the RWTH Aachen
University) using the Affymetrix 1.0 ST gene array
(Affymetrix, Santa Clara, CA).
Profiling of stably transfected MDA-MB-231 breast can-
cer cells was performed using BRB-ArrayTools developed
by Dr. Richard Simon and BRB-ArrayTools Development
Team version 4.3.0 – Beta. In order to identify the signifi-
cantly regulated candidate genes the class comparison
evaluation was used [89], which met the following criteria:
Significantly (p < 0.05) differentially expressed with a min-
imal change in expression by 3-fold. Exact permutation p-
values for significant genes were computed based on 35
available permutations. Genes were excluded when less
than 20% of expression data had at least a 1.5-fold change
in either direction from gene’s median value. Gene Ontol-
ogy (GO) categories were determined by applying a gene
set comparison analysis that is similar to the gene set
enrichment analysis described by Subramanian et al.
[90]. Tests used to find significant gene sets were:
LS/KS permutation test (to find gene sets which have
more genes differentially expressed among the phenotype
classes than expected by chance). Over-represented GO
lists were considered significant when the threshold of
determining significant gene sets is equal or below 0.005
(LS/KS permutation test).
DNA methylation profiling
DNA methylation profiles were analyzed in three inde-
pendent MDA-MB-321 ΔpBK-ITIH5, two mock clones
and WT by using the HumanMethylation450 Beadchip
technology (Illumina, San Diego, USA). Hybridization ofbisulfite converted DNA (200 ng) and initial data evalu-
ation was performed by the DKFZ Gene Core Facility
(Heidelberg, Germany).
Limma-T-test statistics was calculated in R [91] to select
for CpG sites with significant differences in DNA methyla-
tion (adjusted p value <0.05 and 20% differential DNA
methylation level between both test groups). Cluster ana-
lysis of the CpG sites was performed with the “pheatmap
package” for R using complete linkage and Euclidean dis-
tance [92]. The Gene Ontology analysis was performed
using the GOrilla software tool to visualize GO terms of
target (1511 GpG sites) and background list (all analyzed
CpG sites) [93]. Overlap of significantly hyper- and hypo-
methylated CpG sites between ΔpBK-ITIH5 and ΔpBK-
mock clones with gene set data bases was performed using
a public gene set enrichment analysis platform (GSEA;
http://www.broadinstitute.org/gsea/index.jsp) [90, 94]. The
probes / CpG sites of the HumanMethylation450 BeadChip
were furthermore annotated with previously published data
on the presence of two histone H3 modifications
(H3K4Me3 and H3K27Me3) close to a transcription start
site in embryonic stem cells [39]. We used the information
on the probed location (GRC36 reference) provided by the
manufacturer (HumanMethylation450 v1.2 Manifest File).
A promoter region that contained at least one probed
CpG site with a significant difference in DNA methy-
lation level was called deregulated (Additional file 3).
The subsequent analysis was limited to the 12,564
(69%) regions with a minimum of 5 probed CpG sites
to reduce the bias introduced by a low coverage.
Methylation β-values of multiple significant different
methylated CpG sites were averaged after transform-
ation to M-values.
Statistics
Statistical analyses were performed using GraphPad Prism
5.0 (GraphPad Software Inc., La Jolla, CA) and SPSS 20.0
(SPSS, Chicago, IL). Differences were considered statisti-
cally significant if the two sided p-values were equal or
below 5% (≤0.05). To compare two or more groups the
Mann-Whitney or Kruskal-Wallis test was used, respect-
ively. Overall survival (OS) was measured from surgery
until death and was censored for patients alive at the last
follow-up using the univariate log-rank tests.
Additional files
Additional file 1: Cell plasticity of ITIH5-expressing MDA-MB-231
single-cell clones. This figure shows morphological characteristics of
independent MDA-MB-231 single-cell clones using phase-contrast
microscopy. (DOCX 109 kb)
Additional file 2: Overlap of hypo-and hypermethylated CpG sites
with published gene sets (GSEA). This table summarizes an overlap of
significantly hyper- and hypomethylated CpG sites between ΔpBK-ITIH5
and ΔpBK-mock clones with gene set data bases. (XLS 72 kb)
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sites of the HumanMethylation450 BeadChip annotated with histone H3
modifications (H3K4Me3 and H3K27Me3). (XLSX 7866 kb)
Additional file 4: Identified promoter regions with potential H3 marks
that are hyper- or hypomethylated due to ITIH5 expression. This table
illustrates the 242 different promoter regions featuring a significant
association with a potential H3 methylation status described for ES cells.
(XLSX 23 kb)
Additional file 5: Primer sequences and reaction conditions for RT-PCR
experiments. This table illustrates the sequences of all primers used in this
study for RT-PCR analysis. (XLS 28 kb)
Additional file 6: Primer sequences and PCR conditions for MSP
analyses. This table illustrates the sequences of all primers used in this
study for MSP analysis. (XLSX 10 kb)
Additional file 7: Primer sequences for pyrosequencing. This table
shows sequences of DAPK1 pyrosequencing. (XLSX 10 kb)
Additional file 8: Primary antibodies used in this study. This table lists
all primary andtiboides used in this study. (XLS 26 kb)
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